AIMS: To evaluate the prognostic role of the length of a positive surgical margin (+SM) for biochemical recurrence (BCR) after radical prostatectomy (RP) for prostatic cancer. METHODS AND RESULTS: Consecutive RP specimens (n = 267) with +SM were analysed. All RP specimens were sectioned at 4-mm intervals and completely embedded. Data were analysed using Kaplan-Meier survival analysis and proportional hazards models. In 267 patients the length of +SM ranged from 0.4 to 174.5 mm (median 11.2 mm) and correlated with preoperative prostate specific antigen (PSA) (P < 0.001), pathological stage (P < 0.001), tumour volume (P = 0.001), number of +SM (P < 0.001), Gleason grade at +SM (P < 0.001) and Gleason score (P = 0.015). Patients with detectable postoperative PSA levels (n = 34) or adjuvant therapy (n = 59) were excluded from BCR analysis. In the remaining 174 patients the 5-year risk of BCR was 29%; in patients with +SM <or=10 mm and >10 mm this was 21% and 39%, respectively. On multivariable analysis BCR was associated with an increasing length of +SM (<or=10 mm versus >10 mm; hazard ratio 2.15; 95% confidence interval 1.12, 4.15; P = 0.022). CONCLUSIONS: The length of +SM is an independent prognostic factor for BCR in patients with undetectable PSA after RP.
AIMS: To evaluate the prognostic role of the length of a positive surgical margin (+SM) for biochemical recurrence (BCR) after radical prostatectomy (RP) for prostatic cancer. METHODS AND RESULTS: Consecutive RP specimens (n = 267) with +SM were analysed. All RP specimens were sectioned at 4-mm intervals and completely embedded. Data were analysed using Kaplan-Meier survival analysis and proportional hazards models. In 267 patients the length of +SM ranged from 0.4 to 174.5 mm (median 11.2 mm) and correlated with preoperative prostate specific antigen (PSA) (P < 0.001), pathological stage (P < 0.001), tumour volume (P = 0.001), number of +SM (P < 0.001), Gleason grade at +SM (P < 0.001) and Gleason score (P = 0.015). Patients with detectable postoperative PSA levels (n = 34) or adjuvant therapy (n = 59) were excluded from BCR analysis. In the remaining 174 patients the 5-year risk of BCR was 29%; in patients with +SM <or=10 mm and >10 mm this was 21% and 39%, respectively. On multivariable analysis BCR was associated with an increasing length of +SM (<or=10 mm versus >10 mm; hazard ratio 2.15; 95% confidence interval 1.12, 4.15; P = 0.022). CONCLUSIONS: The length of +SM is an independent prognostic factor for BCR in patients with undetectable PSA after RP.
Authors: Heather J Chalfin; Michael Dinizo; Bruce J Trock; Zhaoyong Feng; Alan W Partin; Patrick C Walsh; Elizabeth Humphreys; Misop Han Journal: BJU Int Date: 2012-07-12 Impact factor: 5.588
Authors: Cornelis G van Niekerk; Jeroen A W M van der Laak; Thomas Hambrock; Henk-Jan Huisman; J Alfred Witjes; Jelle O Barentsz; Christina A Hulsbergen-van de Kaa Journal: Eur Radiol Date: 2014-07-18 Impact factor: 5.315
Authors: Margaretha A van der Slot; Michael A den Bakker; Sjoerd Klaver; Mike Kliffen; Martijn B Busstra; John B W Rietbergen; Melanie Gan; Karen E Hamoen; Leo M Budel; Natascha N T Goemaere; Chris H Bangma; Jozien Helleman; Monique J Roobol; Geert J L H van Leenders Journal: Histopathology Date: 2020-09-03 Impact factor: 5.087
Authors: Steven N Seyedin; John M Watkins; Zachary Mayo; Anthony N Snow; Michael Laszewski; J Kyle Russo; Sarah L Mott; Chad R Tracy; Mark C Smith; John M Buatti; Joseph M Caster Journal: Adv Radiat Oncol Date: 2021-08-14
Authors: Shawn Dason; Emily A Vertosick; Kazuma Udo; Daniel D Sjoberg; Andrew J Vickers; Hikmat Al-Ahmadie; Ying-Bei Chen; Anuradha Gopalan; S Joseph Sirintrapun; Satish K Tickoo; Peter T Scardino; James A Eastham; Victor E Reuter; Samson W Fine Journal: BJU Int Date: 2021-07-11 Impact factor: 5.969